Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial

Autor: Maria Gonzalez-Cao, Clara Mayo de las Casas, Juana Oramas, Miguel A. Berciano-Guerrero, Luis de la Cruz, Pablo Cerezuela, Ana Arance, Eva Muñoz-Couselo, Enrique Espinosa, Teresa Puertolas, Roberto Diaz Beveridge, Sebastian Ochenduszko, Maria-Jose Villanueva, Laura Basterretxea, Lorena Bellido, Delvys Rodriguez, Begoña Campos, Clara Montagut, Ana Drozdowskyj, Miguel A. Molina, Jose Antonio Lopez-Martin, Alfonso Berrocal

Publikováno v: Nature Communications, Vol 12, Iss 1, Pp 1-6 (2021)

Whether intermittent strategies of delivering drugs can improve cancer patients survival is still unclear. Here, the authors reports the results of a randomized phase II clinical trial aimed to compare the efficacy and safety of two dosing regimens (

Externí odkaz: https://doaj.org/article/bcf9c314e06143fd83f1b0b564d0166e

Legislación de la formación especializada en Medicina Familiar y Comunitaria.

Autor: Pablo Cerezuela, Francisco José¹

Publikováno v: AMF: Actualización en Medicina de Familia. Dec2022, Vol. 18 Issue 11, p637-645. 9p.

Frequency and Clinicopathological Profile Associated with Braf Mutations in Patients with Advanced Melanoma in Spain

Autor: Jose A. Lopez-Martin, Ana Arance Fernández, Juan José Ríos-Martín, Javier Hernández-Losa, Lucía Alós Hernández, Pablo Cerezuela Fuentes, Sebastián Ortiz Reina, Eugenia Ortega Izquierdo, Rosa M Martí, Jesús Soberino García, Berta Ferrer Fábrega, José Luis Rodríguez Peralto

Publikováno v: Translational Oncology, Vol 13, Iss 6, Pp - (2020)

Real-world data on BRAF mutation frequency in advanced melanoma are lacking in Spain. Moreover, data available on clinicopathological profile of patients with advanced BRAF-mutant melanoma are currently limited. This study aimed to assess the frequen

Externí odkaz: https://doaj.org/article/3bbb0562665e42b2b68b69248b9620e6

Lower limb cutaneous melanoma surgery: location matters

Autor: Antonio Piñero-Madrona, Pablo Cerezuela-Fuentes, Guadalupe Ruiz-Merino, Enrique Martínez-Barba, Sebastián Ortiz-Reina, María José Martínez-Ortiz, Angel López-Ávila, José F. Frías-Iniesta, Alice Viney, Juan Cabezas-Herrera

Publikováno v: Archives of Dermatological Research.

The anatomical location of cutaneous melanoma is a relevant independent prognostic factor in melanoma. The aim of the study is to know the prognosis of lower limb cutaneous melanoma related to their location within the limb, regardless of the histolo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0ade21729837a23a017fcb97d33eb669
https://doi.org/10.1007/s00403-023-02571-z

Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial

Autor: Clara Mayo de las Casas, Maria Gonzalez-Cao, Sebastian Ochenduszko, Juana Oramas, Miguel Angel Molina, Eva Muñoz-Couselo, Ana Arance, Roberto Diaz Beveridge, Miguel A Berciano-Guerrero, Enrique Espinosa, Luis de la Cruz, Delvys Rodriguez, Pablo Cerezuela, Ana Drozdowskyj, L. Bellido, Clara Montagut, Teresa Puertolas, Laura Basterretxea, Jose A. Lopez-Martin, Alfonso Berrocal, Maria-Jose Villanueva, Begoña Campos

Publikováno v: Nature Communications, Vol 12, Iss 1, Pp 1-6 (2021)
Nature Communications
r-FIHGUV. Repositorio Institucional de Producción Científica de la Fundación de Investigación del Hospital General de Valencia
instname
NATURE COMMUNICATIONS
r-FISABIO. Repositorio Institucional de Producción Científica
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe

Combination treatment with BRAF (BRAFi) plus MEK inhibitors (MEKi) has demonstrated survival benefit in patients with advanced melanoma harboring activating BRAF mutations. Previous preclinical studies suggested that an intermittent dosing of these d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8921227b4094a6e83648a83acb6fbd70
https://doaj.org/article/bcf9c314e06143fd83f1b0b564d0166e